Credit: Plano Pte Ltd
Thomson X (TX), a wholly-owned subsidiary of SGX Mainboard-listed Thomson Medical Group Limited, is a platform which aims to bolster the current healthcare landscape by connecting healthcare technological start-ups with their existing healthcare expertise and network. They have established a partnership with Plano, seeking to address the increasing myopia rate around the world through the use of cutting-edge technological solutions. This will help them to scale up more rapidly and maximize their outreach which in turn fuels more sustainable growth. Plano’s vision is to raise awareness about myopia and help manage it through education and the use of innovative technological systems or Artificial Intelligence (AI).
TX ), a wholly-owned subsidiary of SGX Mainboard-listed Thomson Medical Group Limited (the
Group ), today announced a strategic partnership with Plano Pte Ltd (
Plano ), a Singapore-based HealthTech startup. The collaboration will leverage on the respective strengths of TX and Plano to address and manage the rapidly increasing incidence of myopia through innovative technological solutions.
Myopia is steadily growing into one of the biggest public health challenges in the world, affecting an estimated 2.6 billion people globally, or about one-third of the world s population. By 2050, myopia is projected to affect 5 billion people, which is estimated to be about half of the world s population